Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Crystal form of cyclin dependent protein kinase inhibitor and preparation method thereof

A crystallization and solvent technology, applied in organic chemical methods, pharmaceutical formulations, organic active ingredients, etc., can solve problems such as easy agglomeration, poor product stability, and difficult filtration, and achieve repeatable and controllable production processes and stable crystal forms Good and stable production process

Active Publication Date: 2016-11-02
JIANGSU HENGRUI MEDICINE CO LTD
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Generally speaking, amorphous drug products have no regular crystal structure and often have other defects, such as poor product stability, fine crystallization, difficult filtration, easy agglomeration, poor fluidity, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystal form of cyclin dependent protein kinase inhibitor and preparation method thereof
  • Crystal form of cyclin dependent protein kinase inhibitor and preparation method thereof
  • Crystal form of cyclin dependent protein kinase inhibitor and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Take (1.0g, 2.24mmol) the compound represented by formula (I) (prepared according to the method provided by WO2014183520) and add it to a 250ml Erlenmeyer flask, add 40ml ethanol, stir at room temperature, then drop dilute hydrochloric acid (219mg, 6.01mmol) (dissolved in 4ml of water), heated to 60°C, dissolved, dropped into sodium bicarbonate solution (1.21g, 14.40mmol) (dissolved in 40ml of water), cooled to room temperature and stirred overnight. After drying, 0.89 g of solid was obtained, and the yield was 89.0%. The X-ray diffraction spectrum figure of this crystalline sample is shown in figure 1 . The crystallization at about 4.91 (17.99), 9.91 (8.92), 10.53 (8.39), 14.82 (5.98), 16.04 (5.52), 17.34 (5.11), 18.51 (4.79), 19.92 (4.45), 21.19 (4.19), 22.65 (3.92), 24.15(3.68), 26.92(3.31), and 28.98(3.08) have characteristic peaks. See the DSC spectrum figure 2 , with a sharp melting endothermic peak at 289.22°C, this crystal form is defined as I crystal form....

Embodiment 2

[0036] Get (1.0g, 2.24mmol) compound shown in formula (I) (prepared by Example 1) and join in the 250ml Erlenmeyer flask, add 40ml methyl alcohol, stir at room temperature, drop dilute hydrochloric acid (219mg, 6.01mmol) then ( dissolved in 4ml of water), heated to 60°C, dissolved, dropped into sodium bicarbonate solution (1.21g, 14.40mmol) (dissolved in 40ml of water), cooled to room temperature and stirred overnight. After drying, 0.98 g of solid was obtained, and the yield was 98.0%. Its X-diffraction and DSC patterns are researched and compared, and it is confirmed that the product is I crystal form.

Embodiment 3

[0038] Get (1.0g, 2.24mmol) the compound shown in formula (I) (prepared by Example 1) and join in the 250ml Erlenmeyer flask, add 40ml isopropanol, stir at room temperature, then drop dilute hydrochloric acid (219mg, 6.01mmol ) (dissolved in 4ml of water), heated to 60°C, dissolved, dropped into sodium bicarbonate solution (1.21g, 14.40mmol) (dissolved in 40ml of water), cooled to room temperature and stirred overnight. After drying, 0.52 g of solid was obtained, and the yield was 52.0%. Its X-diffraction and DSC patterns are researched and compared, and it is confirmed that the product is I crystal form.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a crystal form of a cyclin dependent protein kinase inhibitor and a preparation method thereof. Specifically, the invention relates to a type I crystal of a cyclin dependent protein kinase (CDK4&6) inhibitor and a preparation method thereof. Specifically, the invention relates to a type I crystal of 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperidine-4-yl)pyridine-2-yl)amino)pyridine[2, 3-d]pyrimidine-7(8H)-one (formula (I) compound) and a preparation method thereof, wherein the crystal has an X-ray powder diffraction spectrum shown as Figure 1. The type I crystal of the formula (I) compound obtained by the invention has good chemical stability and crystal form stability, and the used crystal solvent has low toxicity and low residue, thus being better applicable to clinical treatment. (formula (I)).

Description

technical field [0001] The present invention relates to 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperidin-4-yl)pyridin-2-yl)amino)pyrido[2,3-d] Pyrimidin-7(8H)-one and its I crystal form. The compound of formula (I) prepared according to the method of the present invention can be used for the treatment of breast cancer. Background technique [0002] Breast cancer is one of the most common malignant tumors in women. It has a high incidence rate and is quite invasive, but the course of the disease progresses slowly. On February 1, 2010, the China Population Association released the "China Breast Disease Survey Report" in Beijing. The report shows that, The mortality rate of breast cancer in my country's urban areas has increased by 38.91%. Breast cancer has become the most threatening disease to women's health. Currently, there are at least 156 breast cancer drugs under research and on the market, of which 68% are targeted therapy drugs. A large number of studies It was found t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D471/04A61K31/519A61P35/00
CPCC07B2200/13C07D471/04
Inventor 武乖利郭昌山边林卢韵沈灵佳
Owner JIANGSU HENGRUI MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com